--- title: "Patient acquisition spend ran above what reimbursement paid" description: "Direct to patient test acquisition cost more per patient than reimbursement returned. Marketing & margin audit: $71k/yr in wasted spend cut." url: https://marginfix.ai/cases/patient-acquisition-spend-ran-above-what-reimbursement-paid/ lastmod: 2026-10-24 --- Patient acquisition spend ran above what reimbursement paid. [Request an audit →](/book/) Pharma · Diagnostics # Patient acquisition spend ran above what reimbursement paid. This marketing & margin audit identified **$71k in wasted annual spend** in a Pharma business, evidenced, senior reviewed, and delivered in 7 days. $3–8M annual revenue Diagnostics Focus: Reimbursement vs CAC −$71k wasted spend cut / yr 22% above reimbursement spend (before) 7 days to findings Acquisition cost vs reimbursement per test Before audit 122% → After fix 78% ## The business A diagnostics and lab business ran direct to patient acquisition for certain tests, spending on marketing to bring patients in. The tests were reimbursed at set rates, but acquisition and reimbursement were managed by different teams, so whether the cost of acquiring a patient actually stayed below what reimbursement paid was never reconciled per test. ## What triggered the audit Volume grew while margin didn’t, a mismatch that points to acquisition cost outrunning reimbursement. The audit reconciled patient acquisition cost against the reimbursement received per test, testing whether the marketing spend to bring each patient in was actually covered by what the test paid. ## What the audit found For certain tests, the business was spending more to acquire a patient than reimbursement returned. Because acquisition and reimbursement sat with separate teams, nobody had put the two numbers side by side per test, and when the audit did, several high volume tests showed a patient acquisition cost that exceeded their reimbursement rate, so every patient marketed in on those lines lost money. The growth looked like success, which made scaling it feel right, when in fact scaling deepened the loss. Because the two figures lived in different silos, the shortfall was structurally invisible. Reconciled per test, the below reimbursement acquisition was costing roughly $71k a year. ◉ How we produced this finding MarginFix reached the reimbursement vs CAC finding by reconciling the pharma books against reality, delivery logs, invoices and contracts side by side, until the gap was undeniable and traced to source, then signed off by a named senior auditor before presentation. Data sources: Contracts, invoices, billing records and delivery or fulfillment logs, reconciled against each other, so the exact gap behind reimbursement vs CAC is traced to the specific line driving it rather than estimated from the top down. Key frameworks: Line by line ledger and contract reconciliation, unit economics and cost to serve analysis, framed by Forrester Total Economic Impact (TEI) for evidenced business value, cost and risk. Human validation gate: Every reconciled figure is checked against your own records and signed off by a named senior auditor before it ships. Nothing is reported without a human tracing it to source. Verified against CRM / rep call logs Sample distribution records Territory spend ledger Finance P&L The wasted spend cut / yr was measured like for like over a matched period, reconciled to territory spend in the finance ledger, and signed off by a named senior auditor before publication. Client identity redacted to protect their commercial position. WORKING PAPER ████████ Diagnostics Representative Redacted Acquisition route Cost vs reimbursement GP referred 62% Employer channel 81% Direct to patient 122% wasted spend cut / yr +$70,840 Recurring, recovered every year the fix holds, not a one off. Working paper: acquisition cost vs reimbursement per test traced line by line and reconciled to territory spend in the finance ledger over a matched period. Line items representative and redacted; the recovered figure is the reconciled audit finding. ## What we changed ✓ Reconciled patient acquisition cost against reimbursement per test, exposing exactly which lines were being acquired below what they actually paid. ✓ Capped or cut acquisition spend on the tests whose reimbursement simply can’t cover the cost of bringing a patient in. ✓ Concentrated marketing on the tests where acquisition genuinely clears reimbursement with real margin to spare. ✓ Made acquisition versus reimbursement a monitored metric per test, so below water spend can’t scale unnoticed across the separate acquisition and reimbursement teams the way it had before this was put right. ## The result The published chart shows acquisition cost per test moving from 122% of reimbursement to 78%, a 44 percentage point decrease. Reimbursement, acquisition cost and delivery cost are separate boundaries; the chart does not by itself establish margin after delivery. $71k a year recovered by ensuring patient acquisition stays below what reimbursement pays, an annual figure equal to 12× the $5,950 Audit + Sprint fee. For any diagnostics or healthcare provider, siloed teams are the trap: acquisition and reimbursement managed separately means nobody sees when the cost to bring a patient in exceeds what the test returns. If you’ve never reconciled the two per test, growth may be deepening a loss. A fixed fee audit reconciles it in days, before more volume compounds the shortfall. From kickoff to signed off findings: 7 days. ![Portrait photograph of Cristian Bragau](/assets/founder/cristian-bragau-2026-10.jpg) Reviewed & signed off by: Cristian Bragau Senior Auditor · MarginFix · 10+ years of auditing experience ✓ Anonymized to protect the client · senior reviewed findings · Audit completed between 2024 and 2026, contracted through Cristian Bragau's practice before the MarginFix name existed · Published in the MarginFix library July 21, 2026 · Last reviewed October 24, 2026 ## What the client said PHARMA $71k a year of wasted spend cut in 7 days Acquisition cost vs reimbursement per test: **122% → 78%** “Acquisition and reimbursement sat with different teams, so nobody compared them. Cristian reconciled cost per patient against reimbursement per test: several high volume tests lost money on every patient we marketed in. We capped those.” **CFO · Pharma · Diagnostics** Written approval Under NDA 7 days to findings ![Portrait photograph of Cristian Bragau](/assets/founder/cristian-bragau-2026-10.jpg) **Cristian Bragau** Senior Auditor · signed this audit off [Request an audit →](/book/) [Prefer to talk it through first? Talk to an auditor →](/book/call/) ## More Pharma findings [Congress and KOL sponsorship showed no measurable return, $88k/yr](/cases/congress-and-kol-sponsorship-showed-no-measurable-return/) [Seasonal media weight ignored when the category actually converted, +$60k/yr](/cases/seasonal-media-weight-ignored-when-the-category-actually-con/) [Unbranded search was paying for traffic the brand site already won, −$78k/yr](/cases/unbranded-search-was-paying-for-traffic-the-brand-site-alrea/) [HCP and patient budgets were optimized in isolation, −$64k/yr](/cases/hcp-and-patient-budgets-were-optimised-in-isolation/) [Subscription acquisition ignored regulatory driven churn, +$44k/yr](/cases/subscription-acquisition-ignored-regulatory-driven-churn/) [Detailing and sample spend produced no prescribing lift, −$64k/yr](/cases/detailing-and-sample-spend-produced-no-prescribing-lift/) [The benchmark: what audits recover across 74 cases →](/benchmark/) [All case studies](/case-studies/) [Model a Pharma budget in the wasted ad spend calculator →](/estimator/pharma/)